Latest News

This approach helps distinguish diseases associated with macular atrophy.

NCX 470 is Nicox’s lead dual-mechanism bimatoprost eye drop for lowering IOP in open-angle glaucoma or ocular hypertension.

Insights for diagnosing and managing these visible changes across specialties.

Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.

Tips for optimizing surgical techniques to reduce recurrence and enhance outcomes.

While primary endpoint analysis showed no statistical difference in the rate of change in GA area between AVD-104 versus monthly avacincaptad pegol, 12-month results showed approximately 31% reduction in GA lesion growth rate versus growth rates in sham and natural history rates.

A phase IV study in China found that 22 of 26 patients achieved complete healing of a persistent corneal epithelial defect or corneal ulcer after 8 weeks.

Pre and postclinic routines, time blocking, and the Eisenhower Decision Matrix enhance efficiency in clinical education.

The company plans to submit its NDA package in the second half of 2026.